Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5421 - Evaluation of indoleamine 2,3-dioxygenase expression (IDO), transforming growth factor beta (TGF-β) and interleukin 13 (IL13) expression on clinical outcome in patients with Hodgkin’s lymphoma.


09 Sep 2017


Poster display session


Tetiana Skrypets


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


T. Skrypets1, O. Novosad1, Y. Pastushenko1, O. Skachkova2, O. Gorbach2, N. Khranovska2, I. Kryachok1

Author affiliations

  • 1 Oncohematology, National Cancer Institute of the MPH Ukraine, 3022 - Kiev/UA
  • 2 Laboratory Of Experimental Oncology, National Cancer Institute of the MPH Ukraine, 3022 - Kiev/UA


Abstract 5421


Nowadays, patients with Hodgkin’s lymphoma (HL) have a high cure rate. However, approximately 20% pts have relapse or progressive disease. The main histological feature in HL is presence by Hodgkin Reed-Sternberg (HRS) cells. HRS cells produce a diversity of cytokines and chemokines. There is still a limited information of prognostic role expression of cytokines in patients with HL. We assessed the impact on clinical outcome of the IDO, TGF- β and IL-13 expression in patients with HL.


79 patients (pts) with HL were included in this study (median age: 41, range: 18-65 years; males: 26, females: 53). Early stages of HL have 53.3% and 46.7% pts had advanced stages. Patients were treated with ABVD or BEACOPP (14/esc) and radiation therapy. CR/PR was achieved in 86.1% of patients. 13.9% of pts had relapse or disease progression during the therapy. mRNA expression levels of IDO, TGF-β, IL-13 were measured in fresh pre-treatment tumor tissue specimens from HL patients using real-time qPCR analysis.


25 pts (31.6%) had IDO positive expression (IDO+) and 54 (65.4%) pts was IDO negative (IDO-). Multivariate analysis showed that IDO+ expression correlated with worser EFS rate with HRs of 10.7 [95% confidence interval(CI) 0.4–0.6, p = 0.01], especially in 3-years EFS in IDO+ males comparing to IDO+ females (61% vs 71%, p 


Our data showed that IDO, TGF-β and IL13 expressions have a role in predicting clinical outcome in pts with HL. Positive expression of IDO, TGF-β and high expression level of IL13 could be considered as a negative prognostic marker. Significantly worser outcome had pts with positive expression of two cytokines comparing with patients, who had only one positive marker.

Clinical trial identification

Legal entity responsible for the study

T. Skrypets




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.